

Supplementary Online Content

Lee T-Y, Hsu Y-C, Tseng H-C, et al. Association of daily aspirin therapy with risk of hepatocellular carcinoma in patients with chronic hepatitis B. *JAMA Intern Med*. Published online March 18, 2019.
doi:10.1001/jamainternmed.2018.8342

eMethods. The ICD Codes Used in This Study

eFigure 1. Cumulative Incidence of Hepatocellular Carcinoma Development in Aspirin-Treated (Continuous Aspirin Use for at Least 1 Year) or Untreated Groups

eFigure 2. Cumulative Incidence of Hepatocellular Carcinoma Development in Aspirin-Treated (Continuous Aspirin Use for at Least 2 Years) or Untreated Groups

eFigure 3. Cumulative Incidence of Peptic Ulcer Bleeding in the Aspirin-Treated or Untreated Groups

eFigure 4. Cumulative incidence of Peptic Ulcer Bleeding Among Cirrhotic or Non-Cirrhotic Patients in the Aspirin-Treated Group

eFigure 5. Cumulative Incidence of Peptic Ulcer Bleeding in Typical Aspirin Users With Liver Disease (Chronic Hepatitis B) or Without Liver Disease

eTable. Demographic Characteristics of Typical Patients Who Received Daily Aspirin Therapy for Cardiovascular Diseases

eFigure 6. Cumulative Incidence of Suicide in the Aspirin-Treated or Untreated Groups

eFigure 7. Cumulative Incidence of Hip Fracture in the Aspirin-Treated or Untreated Groups

eFigure 8. The Proportion of Patients Continuing Aspirin Therapy During the Study Period


This supplementary material has been provided by the authors to give readers additional information about their work.

eMethods. The ICD Codes Used in This Study

		ICD9-CODE
1	Chronic hepatitis B	【070.2】 【070.3】 【V02.61】
2	Chronic hepatitis C	【07041】 【07044】 【07051】 【07054】 【V0262】 【070.7】
3	Other viral hepatitis	【573.2】 【573.1】
4	Human immunodeficiency virus disease	【042】
5	Alcoholic liver disease	【571.0】 【571.3】
6	Cirrhosis	【571.2】 【571.5】 【571.6】
7	Liver decompensation	【789.5】 【572.2】 【572.4】
8	Diabetes mellitus	【250】 【648.0】
9	Hyperlipidemia	【272.0】 – 【272.4】
10	Hypertension	【401】 – 【405】
11	Coronary arterial disease	【410】 – 【414】
12	Cerebral vascular disease	【430】 – 【438】
13	Cardiac dysrhythmias	【427】
14	Peripheral vascular disease	【443】
15	Hepatocellular carcinoma	【155.0】
16	Peptic ulcer bleeding	【531.0】 【531.1】 【531.2】 【531.4】 【531.5】 【531.6】 【532.0】 【532.1】 【532.2】 【532.4】 【532.5】 【532.6】 【533.0】 【533.1】 【533.2】 【533.4】 【533.5】 【533.6】 【534.0】 【534.1】 【534.2】 【534.4】 【534.5】 【534.6】
17	Suicide	【E950】 – 【E958】 【E980】 – 【E988】
18	Hip fracture	【820】 【733.14】 【733.96】

eFigure 1. Cumulative Incidence of Hepatocellular Carcinoma Development in Aspirin-Treated (Continuous Aspirin Use for at Least 1 Year) or Untreated Groups


Follow-up from 1 year after the initiation of aspirin therapy.



Number at risk		Follow-up (years)					
	0	1	2	3	4	5	
Untreated	5112	3894	3026	2230	1622	1133	
Treated	1278	1120	994	838	684	571	

eFigure 2. Cumulative Incidence of Hepatocellular Carcinoma Development in Aspirin-Treated (Continuous Aspirin Use for at Least 2 Years) or Untreated Groups


Follow-up from 2 years after the initiation of aspirin therapy.



Number at risk		Follow-up (years)					
	0	1	2	3	4	5	
Untreated	3872	2913	2038	1451	1040	730	
Treated	968	853	715	577	489	386	

eFigure 3. Cumulative Incidence of Peptic Ulcer Bleeding in the Aspirin-Treated or Untreated Groups


Follow-up from the initiation of aspirin therapy.



Number at risk		Follow-up (years)					
	0	1	2	3	4	5	
Untreated	8492	8084	7096	6249	5036	4048	
Treated	2123	2054	1901	1747	1508	1293	

eFigure 4. Cumulative incidence of Peptic Ulcer Bleeding Among Cirrhotic or Non-Cirrhotic Patients in the Aspirin-Treated Group


Follow-up from the initiation of aspirin therapy.



Number at risk		Follow-up (years)					
	0	1	2	3	4	5	
Cirrhotic	362	348	324	295	265	242	
Non-cirrhotic	1761	1706	1577	1452	1243	1051	

eFigure 5. Cumulative Incidence of Peptic Ulcer Bleeding in Typical Aspirin Users With Liver Disease (Chronic Hepatitis B) or Without Liver Disease

Follow-up from the initiation of aspirin therapy.



		Follow-up (years)					
Number at risk		0	1	2	3	4	5
No liver disease		6724	6438	6102	5722	5143	4469
Liver disease		1681	1559	1407	1261	1034	847


eTable. Demographic Characteristics of Typical Patients Who Received Daily Aspirin**Therapy for Cardiovascular Diseases**

Characteristics	Liver disease n = 1,681	No liver diseases n = 6,724	P value
Age, years			
Mean ± SD	60.9 ± 11.5	60.8 ± 11.5	0.69
Median (IQR)	61.4 (52.4-69.4)	61.4 (52.2-69.3)	0.72
Sex, n (%)			0.87
Male	1241 (73.8%)	4948 (73.6%)	
Female	440 (26.2%)	1776 (26.4%)	
Underlying comorbidities, n (%)			
Coronary arterial disease	603 (35.9%)	2475 (36.8%)	0.49
Cerebral vascular disease	733 (43.6%)	2928 (43.6%)	0.99
Diabetes mellitus	802 (47.7%)	3274 (48.7%)	0.49
Hyperlipidemia	606 (36.1%)	2424 (36.1%)	1.00
Hypertension	1156 (68.8%)	4642 (69.0%)	0.86
Drug use			
Metformin	603 (35.9%)	2477 (36.8%)	0.48
Statin	507 (30.16)	2119 (31.5%)	0.30
Proton pump inhibitor	4 (0.24%)	16 (0.24%)	1.00
NSAID	277 (16.5%)	1008 (15.0%)	0.14

Abbreviations: SD, standard deviation; IQR, interquartile range; NSAID: non-steroidal anti-inflammatory drug

eFigure 6. Cumulative Incidence of Suicide in the Aspirin-Treated or Untreated Groups


Follow-up from the initiation of aspirin therapy.



Number at risk		Follow-up (years)					
	0	1	2	3	4	5	
Untreated	8492	8011	6479	5314	4002	3005	
Treated	2123	2060	1838	1624	1352	1110	

eFigure 7. Cumulative Incidence of Hip Fracture in the Aspirin-Treated or Untreated Groups


Follow-up from the initiation of aspirin therapy



Number at risk		Follow-up (years)					
		0	1	2	3	4	5
Untreated		8492	7981	6440	5280	3976	2989
Treated		2123	2056	1833	1613	1340	1093

eFigure 8. The Proportion of Patients Continuing Aspirin Therapy During the Study Period

Follow-up from the initiation of aspirin therapy.



Case number	2123	2056	1817	1595	1324	1082
-------------	------	------	------	------	------	------